Extra-helical binding site of a glucagon receptor antagonist
Autor: | Robert M. Cooke, Nathan Robertson, Markus Koglin, Harini Krishnamurthy, Ali Jazayeri, Asma H. Baig, Andrea Bortolato, Malcolm Peter Weir, A.S. Dore, Stacey M. Southall, Fiona H. Marshall, Iryna Teobald, Alastair J. H. Brown, Daniel Lamb, James C. Errey, Stephen P. Andrews |
---|---|
Rok vydání: | 2016 |
Předmět: |
Models
Molecular 0301 basic medicine medicine.medical_specialty Protein Conformation Lipid Bilayers Allosteric regulation Biology Crystallography X-Ray Ligands Receptors Corticotropin-Releasing Hormone Glucagon 03 medical and health sciences 0302 clinical medicine Internal medicine Receptors Glucagon medicine Humans Glucose homeostasis Receptor Glucagon-like peptide 1 receptor G protein-coupled receptor Multidisciplinary 030104 developmental biology Endocrinology beta-Alanine Pyrazoles Glucagon receptor Glucagon receptor family Allosteric Site 030217 neurology & neurosurgery |
Zdroj: | Nature. 533:274-277 |
ISSN: | 1476-4687 0028-0836 |
DOI: | 10.1038/nature17414 |
Popis: | Glucagon is a 29-amino-acid peptide released from the α-cells of the islet of Langerhans, which has a key role in glucose homeostasis. Glucagon action is transduced by the class B G-protein-coupled glucagon receptor (GCGR), which is located on liver, kidney, intestinal smooth muscle, brain, adipose tissue, heart and pancreas cells, and this receptor has been considered an important drug target in the treatment of diabetes. Administration of recently identified small-molecule GCGR antagonists in patients with type 2 diabetes results in a substantial reduction of fasting and postprandial glucose concentrations. Although an X-ray structure of the transmembrane domain of the GCGR has previously been solved, the ligand (NNC0640) was not resolved. Here we report the 2.5 Å structure of human GCGR in complex with the antagonist MK-0893 (ref. 4), which is found to bind to an allosteric site outside the seven transmembrane (7TM) helical bundle in a position between TM6 and TM7 extending into the lipid bilayer. Mutagenesis of key residues identified in the X-ray structure confirms their role in the binding of MK-0893 to the receptor. The unexpected position of the binding site for MK-0893, which is structurally similar to other GCGR antagonists, suggests that glucagon activation of the receptor is prevented by restriction of the outward helical movement of TM6 required for G-protein coupling. Structural knowledge of class B receptors is limited, with only one other ligand-binding site defined--for the corticotropin-releasing hormone receptor 1 (CRF1R)--which was located deep within the 7TM bundle. We describe a completely novel allosteric binding site for class B receptors, providing an opportunity for structure-based drug design for this receptor class and furthering our understanding of the mechanisms of activation of these receptors. |
Databáze: | OpenAIRE |
Externí odkaz: |